Based on our transcriptome findings, validated in immunocompetent models, MAPK mutations likely identify highly CD8+ T-cell–inflamed/cytolytically active HNSCC patients who may potentially benefit from ICIs. Here, CD8A is linked to head and neck squamous cell carcinoma.